|Day Low/High||6.62 / 7.20|
|52 Wk Low/High||4.98 / 18.40|
Amicus Therapeutics (FOLD) CEO John Crowley joined Thursday morning's 'Squawk Box' on CNBC to discuss the future of the company and new medications in the pipeline.
Amicus Therapeutics (FOLD) reported a wider-than-expected loss for the 2016 second quarter before Tuesday's market open.
Potential First-in-Class Protein Replacement Therapy for Devastating Rare Genetic Neurological Disorder with No Approved Treatments
As Brexit turmoil calms down, let's get back to small cap stocks.
Investors considering a purchase of Amicus Therapeutics Inc stock, but cautious about paying the going market price of $6.02/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 55 cents.
Re-Elects John F. Crowley, Margaret G. McGlynn, Michael G. Raab, and Glenn P. Sblendorio
These under-$10 stocks are within range of triggering big breakout trades.
Investors give the side eye to a prediction from Chardan analyst Gbola Amusa that Amicus Therapeutics will be acquired for three times its current market value
Amicus (FOLD) stock is surging this afternoon after a European regulator recommended approving the company's Fabry disease treatment.
A committee of European drug reviewers voted Friday to recommend the approval of the first oral treatment for Fabry disease, developed by Amicus Therapeutics.
These stocks trading for less than $10 a share are within range of triggering big breakout trades.
Investors in Amicus Therapeutics Inc saw new options begin trading this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new May 20th contracts and identified one put and one call contract of particular interest.